Shots: Shionogi announced a planned acquisition of IntraBio for $2.0B, adding AQNEURSA (levacetylleucine) and IntraBio’s rare disease capabilities to its portfolio; the transaction is expected to close between November and December 2026, subject to customary conditions and regulatory approvals AQNEURSA is approved in the US and EU for neurological manifestations of Niemann-Pick disease Type C…